TFS Trial Form Support

What TFS Trial Form Support does

TFS HealthScience (legally TFS Trial Form Support AB) is a privately held, full-service global Contract Research Organization founded in 1996 in Lund, Sweden, and wholly owned by Swedish private equity firm Ratos since 2019. With nearly 700 professionals operating across 50 countries and 24+ owned offices spanning North America, Europe, the Middle East, and Asia-Pacific, TFS delivers Phase I–IV clinical development, real-world evidence studies, functional service provider (FSP) outsourcing, and strategic resourcing solutions to biotech and pharmaceutical sponsors. Its core products include Clinical Development Services, the TFS ReAL (Real World Evidence) platform, the TFS-RWE Algorithm for protocol optimization, and Strategic Resourcing Solutions spanning single-resource insourcing to fully managed teams; these are organized around five therapeutic specialties: Dermatology, Internal Medicine, Neuroscience, Oncology, and Ophthalmology.

The technology stack integrates an EDC/CTMS/eTMF clinical trial management platform with AI-driven patient targeting, decentralized trial capabilities (eConsent, ePRO/eDiary, eVisits, wearables), and proprietary RWE analytics combining structured data ML with NLP for unstructured records. Therapeutic track record is material to credibility: 400+ dermatology trials, 350+ internal medicine trials, 300+ oncology trials, 140+ neuroscience trials, 70+ ophthalmology trials, and 250+ RWE/Phase IV studies, executed across 8,000+ trial sites and enrolling more than 300,000 patients cumulatively.

TFS makes money through professional services and managed services contracts priced on a quote-based, custom engagement model tailored to each sponsor's therapeutic area, study complexity, and scope of services; pricing is not publicly disclosed. Distribution is exclusively direct enterprise field sales, augmented by event-driven demand generation at ESMO, EADV, AAO, ARVO, CNS Summit, and related conferences, with digital content marketing and a global investigator database as community-building assets. The company has executed six strategic acquisitions since 2005 (most recently Appletree CI Group in 2023) and formalized a 2026 partnership with VERIGRAFT on an Advanced Therapy Medicinal Product trial.

Name

TFS Trial Form Support

Legal name

TFS Trial Form Support AB Group

Website

https://tfscro.com

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

501–1,000 employees

Short description

TFS HealthScience is a global mid-size Contract Research Organization, wholly owned by Ratos since 2019, that delivers Phase I–IV clinical development, real-world evidence, FSP outsourcing, and strategic resourcing to biotech and pharma sponsors across five therapeutic specialties: Dermatology, Internal Medicine, Neuroscience, Oncology, and Ophthalmology.

Ownership category

akta.pro rank

Headquarters

HQ city

Lund

HQ country

Sweden

HQ region

Europe

Offices24 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Clinical Development Services: Full-service Phase I-III and Phase IV/Real World Evidence clinical trial management for biotech and pharmaceutical sponsors. Covers regulatory strategy, clinical operations, site management, data management, biostatistics, medical writing, drug safety, and quality compliance.
2. Functional Services (FSP): Fit-for-purpose FSP outsourcing models providing embedded or dedicated teams for specific clinical functions (project management, regulatory, clinical monitoring, data management, medical writing, drug safety, quality). Delivered through flexible pricing models scaling from single service to full functional outsourcing.
3. Strategic Resourcing Solutions: Flexible staffing and recruitment services providing individual talent experts or entire managed teams. Includes professional insourcing (short- and long-term) and permanent recruitment services across all clinical development functions and seniority levels.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels8 records

Core offering

TFS HealthScience (legal entity: TFS Trial Form Support AB) is a global mid-size Contract Research Organization (CRO) that delivers full-service clinical development solutions, functional service provider (FSP) outsourcing models, and strategic resourcing services to biotech and pharmaceutical sponsors. The company operates across Phase I–IV and real-world evidence studies, supported by proprietary platforms including TFS ReAL for RWE and integrated CTMS/EDC/eTMF systems, with therapeutic specialization in dermatology, internal medicine, neuroscience, oncology, and ophthalmology.

Product overview

TFS HealthScience is a full-service global Contract Research Organization (CRO) offering a unified platform of clinical development and resourcing solutions. The core portfolio centers on Clinical Development Services combined with Functional Services (FSP) and Strategic Resourcing Solutions, supported by specialized Therapeutic Area CRO Services in Dermatology, Internal Medicine, Neuroscience, Oncology, and Ophthalmology. Key product lines include TFS ReAL (Real World Evidence platform) for late-phase and RWE studies, investigator database for site network management, and Phase I-IV clinical trial services. The company operates with nearly 700 professionals across 50 countries, delivering tailored solutions from early-phase planning through post-authorization studies.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Development Services Full-service clinical development solutions covering regulatory strategy, clinical operations, Phase I–III trials, and post-authorization studies with scientific and operational expertise tailored to project needs. Targeted at biotech and pharmaceutical sponsors across five core therapeutic areas.
• Functional Services (FSP) Fit-for-purpose FSP outsourcing models for clinical workforce management, ranging from global end-to-end development to single services, with embedded team approach and flexible pricing.
• Strategic Resourcing Solutions

Quantifiable outcome

• 400+ completed dermatology clinical trials with 85,000+ patients across 8,000+ sites
• +6 more outcomes

Named customers1 record

Segments7 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability7 records

Feature6 records

Partnerships

Eleven partnerships are on record, tiered core, minor and strategic.

• VERIGRAFTcoreStrategic or Co-development Partner · 28 May 2026TFS HealthScience and VERIGRAFT partnered on the pivotal Phase II/III trial of P-TEV (personalized tissue-engineered vein) for chronic venous insufficiency (CVI). TFS provides full-service CRO support including regulatory navigation, site management, clinical operations, and operational expertise for this advanced therapy medicinal product (ATMP). The trial is designed to evaluate the safety, functionality, and long-term performance of the personalized tissue-engineered vein graft in patients with failing deep venous valves.
• Appletree CI GroupcoreStrategic or Co-development Partner · 1 January 2023TFS acquired Swiss-based Appletree CI Group in 2023, expanding its expertise in ophthalmology and medical devices. This acquisition strengthened TFS's capabilities in eye health clinical development and broadened its therapeutic portfolio.
• GCP Clinical Studies (Israel)minorStrategic or Co-development Partner · 1 January 2023TFS formalized its agreement with GCP Clinical Studies in Israel in 2023, expanding its footprint in the Israeli market through an established local partner.
• Duke Clinical Research Institute (DCRI)strategicTechnology or Integration · 1 January 2020TFS partnered with DCRI to provide data management solutions across the academic research organization's study portfolio, integrating TFS's data management expertise with DCRI's academic research capabilities.
• VeevastrategicTechnology or Integration · 1 January 2020TFS partnered with Veeva to offer a safety database solution for its clinical trials, integrating Veeva's safety technology platform into TFS's service offering.
• Medidata (Rave EDC)strategicTechnology or Integration · 1 January 2019TFS joined the Medidata Partner Program with Rave EDC accreditation, enabling TFS to leverage Medidata's electronic data capture platform for client clinical trials.
• SCIdermcoreStrategic or Co-development Partner · 1 January 2016TFS acquired SCIderm, a dermatology specialist CRO, in 2016, expanding its operations in Germany and deepening its therapeutic expertise in dermatology clinical research.
• Beardsworth Consulting Group (US)coreStrategic or Co-development Partner · 1 January 2013TFS acquired Beardsworth Consulting Group in the US, an oncology and vaccine niche CRO, strengthening TFS's oncology and vaccine capabilities.
• Dimensione Ricerca S.r.l (Italy)coreStrategic or Co-development Partner · 1 January 2012TFS acquired Dimensione Ricerca S.r.l, the first established CRO in Italy, expanding its European footprint and adding Italian regulatory and clinical operations expertise.
• IMRO-TRAMARKO (Netherlands)coreStrategic or Co-development Partner · 1 January 2008TFS acquired IMRO-TRAMARKO, the first established CRO in the Netherlands, expanding operations to Benelux and Germany.
• CDC Clinical Data CarecoreStrategic or Co-development Partner · 1 January 2005TFS acquired CDC Clinical Data Care in 2005 to strengthen regulatory, pharmacovigilance, and medical writing services, also expanding into Spain through the acquisition of Clinical Data Care, Spain.

Scale indicators16 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Medpace: US-based mid-size full-service CRO with comparable therapeutic specialization and biotech/pharma focus. Closely comparable business model and target customer base, but larger and US-public, illustrating both the bull and scale-gap cases for TFS.
• Syneos Health: Large biopharmaceutical solutions organization combining CRO services with commercial. Direct overlap on clinical development and FSP/resourcing, and competitor for biotech sponsors at the upper-mid end of the market.
• Worldwide Clinical Trials: Mid-size global CRO focused on complex therapeutic areas including neuroscience, oncology, and rare disease — directly comparable therapeutic mix and biotech sponsor overlap with TFS.

Broad incumbents

• Parexel: Large global CRO with full-service clinical development, FSP, and biopharma services. Comparable in offering breadth and biotech/pharma customer overlap, but at materially greater scale following EQT/GS take-private.
• ICON plc: Top-tier global CRO offering full-service clinical development, FSP, labs, and post-approval services. Major scale competitor that can match TFS across the full funnel and pressures mid-size players on large programs.
• Fortrea (formerly LabCorp Drug Development / Covance): Mid-large full-service CRO spun out of LabCorp in 2023. Closely comparable service portfolio across clinical development, FSP, and resourcing, and a key scale competitor for mid-size CRO opportunities.
• IQVIA: Largest global CRO/biopharma services platform with unmatched data, technology, and operational scale. Sets the upper-bound ceiling on what TFS can competitively bid for in mega-trial mandates.
• Charles River Laboratories: Global CRO/nonclinical discovery and safety assessment provider with growing clinical services footprint. Comparable customer base in biotech/pharma, with deeper upstream discovery integration than TFS.

Regional players

• KCR CRO: European-headquartered mid-size CRO with comparable therapeutic specialization (oncology, dermatology, rare disease) and biotech sponsor focus. Direct regional peer in Europe and a comparable scale benchmark.

Emerging players

• Caidya (formerly dMed / Clinipace): Mid-size global CRO with strong Asia-Pacific and US presence, focused on biotech sponsors. Comparable therapeutic breadth and biotech customer overlap, and an active consolidator in the mid-size segment.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/tfscro
• YouTubeyoutube.com/channel/UCcVDjyWctQdKX4PhBX5Ll4A
• Facebookfacebook.com/tfscrocom
• LinkedInlinkedin.com/company/tfs-trial-form-support

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TFS Trial Form Support